The survival significance of a measurable enhancing lesion after completing standard treatment for newly diagnosed glioblastoma
详细信息 查看全文
- 作者：Sung Kwon Kimh ; Tae Min Kimb ; g ; Soon-Tae Leec ; f ; Se-Hoon Leeb ; g ; Dae Seog Heob ; g ; Il Han Kimd ; g ; Dong Gyu Kimb ; f ; Hee-Won Junga ; f ; Seung Hong Choie ; f ; Sang Hyung Leea ; i ; nslee@snu.ac.kr" class="auth_mail" title="E-mail the corresponding author ; Chul-Kee Parka ; f ; nsckpark@snu.ac.kr" class="auth_mail" title="E-mail the corresponding author
- 关键词：Adjuvant temozolomide ; Glioblastoma ; Measurable enhancing lesion ; Prolonged temozolomide ; Standard treatment
- 刊名：Journal of Clinical Neuroscience
- 出版年：2016
- 出版时间：December 2016
- 年：2016
- 卷：34
- 期：Complete
- 页码：145-150
- 全文大小：935 K
文摘
- •
Natural prognosis in patients with a residual lesion after standard treatment for newly diagnosed glioblastoma, is unclear.
- •
Poor survival outcome was found only in patients who exhibited progressive disease after standard treatment.
- •
No further management may be needed for a patient who shows partial remission or standard disease after standard treatment.